2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)(Cat. No. CD0-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).
2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).
Rituximab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 5.48 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Rituximab | R-105; RG-105; IDEC-102; IDEC-C2B8; RO-452294 | Approved | Biogen Inc | 美罗华, Ristova, Rituxan, MabThera, MabThera/Rituxan | EU | Burkitt Lymphoma; Lymphoma, Large B-Cell, Diffuse | Roche Registration Gmbh | 1997-11-26 | Multiple Sclerosis; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus; Nephrotic Syndrome; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Granulomatosis with Polyangiitis; Lupus Nephritis; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Rejection of liver transplantation; Microscopic Polyangiitis; Rejection of renal transplantation; Purpura, Thrombocytopenic, Idiopathic | Details |
Ibritumomab tiuxetan | IDEC-In2B8; BAY86-5128; SHL-749; IDEC-Y2B8; IDEC-129; IDEC-2B8-MX-DTPA | Approved | Biogen Inc | Zevalin, Zavalin | Japan | Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell | Mundipharma Kk | 2002-02-19 | Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Reliance Life Sciences) | R-TPR-017 | Approved | Reliance Life Sciences | Toritz, RituxiRel | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | null | 2016-01-01 | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Center of Molecular Immunology) | Approved | Center Of Molecular Immunology | CIMAbior, RituxCIM | Cuba | Lymphoma, Non-Hodgkin | null | 2017-04-01 | Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biocad) | BCD-020 | Approved | Biocad | Acellbia | Russian Federation | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin | Biocad | 2015-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (mAbxience) | RTXM-83; mAbx-02 | Approved | Mabxience | Novex | Argentina | Lymphoma, Large B-Cell, Diffuse | Mabxience | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse | Details |
Rituximab biosimilar (Amgen) | ABP-798; APB-798 | Approved | Amgen Inc | Riabni | United States | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Follicular | Amgen Inc | 2020-12-17 | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Pfizer) | PF-05280586; PF-5280586 | Approved | Pfizer Pharmaceuticals Ltd (China) | Ruxience | EU | Lymphoma, Non-Hodgkin; Pemphigus; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis | Pfizer Europe Ma Eeig | 2019-07-23 | Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
rituximab biosimilar (Zenotech) | Approved | Zenotech Laboratories | India | Lymphoma, Non-Hodgkin | Zenotech Laboratories | 2013-02-01 | Lymphoma, Non-Hodgkin | Details | ||
Rituximab biosimilar (AryoGen Biopharma) | Approved | Aryogen Biopharma | Zytux | Iran | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Aryogen Biopharma | 2014-01-01 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Shanghai Henlius Biotech) | HLX-01 | Approved | Shanghai Henlius Biotech Co Ltd | 汉利康 | Mainland China | Lymphoma, Non-Hodgkin | Shanghai Henlius Biopharmaceuticals Co Ltd | 2019-02-22 | Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Mabtas | India | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Intas Biopharmaceuticals | 2013-01-01 | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Dr Reddy's Laboratories) | Approved | Dr. Reddy’S Laboratories Ltd | Reditux, Tidecron | India | Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid | Dr. Reddy’S Laboratories Ltd | 2007-01-01 | Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Biosidus) | Approved | Biosidus | Argentina | Hematologic Neoplasms | Biosidus | 2013-06-01 | Hematologic Neoplasms | Details | ||
Rituximab biosimilar (Hetero Drugs) | Approved | Hetero Drugs | Maball, Mabura | India | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Hetero Drugs | 2015-01-01 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Innovent Biologics) | IBI-301 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯华, HALPRYZA | Mainland China | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Innovent Biologics(Suzhou) Co Ltd | 2020-09-30 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Rituximab biosimilar (Probiomed) | PBO-326 | Approved | Probiomed | Kikuzubam | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details | ||||
Hyaluronidase/Rituximab | Approved | Genentech Inc | Rituxan Hycela | United States | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Genentech Inc | 2017-06-22 | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Celltrion) | CT-P10 | Approved | Celltrion | Truxima, Blitzima, Ritemvia, Rituzena | EU | Pemphigus | Celltrion Healthcare Hungary Kft | 2017-02-17 | Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Ofatumumab | OMB-157; HuMax-CD2; GSK-1841157; 2F2 | Approved | Genmab | Arzerra, Kesimpta | Mainland China | Multiple Sclerosis, Relapsing-Remitting | Beijing Novartis Pharma Co Ltd | 2009-10-26 | Multiple Sclerosis, Relapsing-Remitting; Leukemia; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Follicular; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
Ocrelizumab | R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 | Approved | Genentech Inc | Ocrevus | EU | Multiple Sclerosis | Roche Registration Gmbh | 2017-03-28 | Multiple Sclerosis, Relapsing-Remitting; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lymphoma, Non-Hodgkin | Details |
Obinutuzumab | RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 | Approved | Genentech Inc | Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 | EU | Lymphoma, Follicular | F. Hoffmann-La Roche Ltd | 2013-11-01 | Lupus Nephritis; Carcinoma, Non-Small-Cell Lung; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, B-Cell; Glomerulonephritis, Membranous; Lymphoma, Large B-Cell, Diffuse; Nephrosis; Leukemia, Lymphoid; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Solid tumours | Details |
Rituximab biosimilar (Sandoz) | GP-2013 | Approved | Sandoz | Riximyo, Rixathon | Japan | Lymphoma, Non-Hodgkin; Granulomatosis with Polyangiitis; Microscopic Polyangiitis | Clariant Produkte (Schweiz) Ag | 2017-06-15 | Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Rituximab biosimilar (CTTQ Pharma) | TQB-2303 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
DI-Leu16-IL2 | DI-Leu16-IL2 | Phase 2 Clinical | Merck Serono | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) | BAT-4306F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Lymphoma, Non-Hodgkin | Details |
CAR-20-19-22(Medical College of Wisconsin) | CAR-20-19-22 | The Medical College Of Wisconsin Nonprofit | Details | ||
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics | Lymphoma, B-Cell; Leukemia; Leukemia, B-Cell | Details | |
Rituximab biosimilar (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Arthritis, Rheumatoid; Lymphoma | Details | |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Details | |||
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Non-Hodgkin | Details | |
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (International Biotech Center Generium) | GNR-006 | Phase 1 Clinical | International Biotech Center Generium | Lymphoma, B-Cell | Details |
Rituximab biosimilar (Gedeon Richter) | RGB-03 | Phase 1 Clinical | Gedeon Richter | Arthritis, Rheumatoid | Details |
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) | Phase 1 Clinical | Hebei Yanda Hospital | Lymphoma, B-Cell | Details | |
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia; Lymphoma, B-Cell | Details | |
MB-CART20.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Non-Hodgkin; Melanoma | Details | |
Rituximab biosimilar (Boehringer Ingelheim) | BI-695500 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) | CART-20; CBM-C20.1; CBM-CD20 1 | Phase 2 Clinical | Pla General Hospital | Leukemia; Lymphoma, B-Cell | Details |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
BAT-4406F | BAT-4406; BAT-4406F | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neuromyelitis Optica | Details |
Bendamustine Hydrochloride/Rituximab | Phase 1 Clinical | 1globe Biomedical Co Ltd | Lymphoma, B-Cell | Details | |
CD20-directed CAR-T cell therapy (Tongji Hospital) | C-CAR066 | Phase 1 Clinical | Tongji Hospital | Lymphoma, B-Cell | Details |
ACTR-707 | Phase 1 Clinical | Unum Therapeutics | Solid tumours; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) | PBCAR-20A | Phase 2 Clinical | Precision Biosciences | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
TRS-005 | TRS-005 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma, Non-Hodgkin | Details |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Neoplasms | Details | |
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) | Phase 2 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) | TRS001 | Phase 1 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Lymphoma | Details |
IMM-0306 | IMM-0306 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Lymphoma, B-Cell | Details |
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) | Clinical | Wuhan Bio-Raid Biotechnology | Neoplasms | Details | |
Ocrelizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Multiple Sclerosis | Details | |
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details | |
Rituximab biosimilar (Genor Biopharma) | GB-241 | Phase 3 Clinical | Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
Veltuzumab | hA20; IMMU-106 | Phase 2 Clinical | Immunomedics Inc | Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Leukemia, Lymphoid; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Pain, Postoperative; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details |
Rituximab conjugate (BioIntegrator) | CON-4619 | Phase 1 Clinical | Biointegrator | Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) | LZM-002 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Hematologic Neoplasms | Details | |
LY007 | LY007 | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
MB-106 | MB-106 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, Non-Hodgkin | Details |
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Multicentric Castleman's Disease (MCD); Sarcoma, Kaposi | Details | |
BVX20-CD20 antibody (Biocon/Vaccinex) | BVX-20; BVX20-MAb | Phase 2 Clinical | Biocon, Vaccinex | Lymphoma, Non-Hodgkin | Details |
Rituximab Biosimilar (Istituto Giannina Gaslini) | Istituto Giannina Gaslini | Details | |||
CPO-107 | Phase 2 Clinical | Conjupro Biotherapeutics Inc | Lymphoma, Non-Hodgkin | Details | |
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) | LUCAR-20S | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Divozilimab | BCD-132 | Phase 2 Clinical | Biocad | Multiple Sclerosis | Details |
TanCART19/20 | Phase 1 Clinical | The General Hospital Of The People'S Liberation Army | Neuromyelitis Optica | Details | |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
C-CAR039 | EXP-039; C-CAR039; C-CAR-039 | Phase 1 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, Non-Hodgkin | Details |
EX-103 | EX-103; EX103 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) | B-007 | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd | Lymphoma, Non-Hodgkin | Details |
Plamotamab | XmAb-13676 | Phase 1 Clinical | Xencor | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD20 x CD3 bispecific antibody (IGM Biosciences) | IGM-2323 | Phase 1 Clinical | Igm Biosciences | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details |
TQB-2825 | TQB-2825 | Phase 1 Clinical | Wuxi Biologics Co Ltd | Hematologic Neoplasms | Details |
GB-261 | GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
SNG2005 | SNG-2005 | Phase 1 Clinical | Alopexx Oncology | Lymphoma, B-Cell | Details |
Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Lymphoma, Non-Hodgkin | Details |
Rituximab biosimilar (Samsung) | SAIT-101 | Phase 3 Clinical | Samsung Biologics | Arthritis, Rheumatoid; Lymphoma, Follicular | Details |
ADI-001 | ADI-001 | Phase 1 Clinical | Adicet Bio Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin | Details |
1-A-46 | 1-A-46; CMG1A46; CMG1A-46; BR110; 1A46 | Phase 1 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd | Lymphoma, Non-Hodgkin | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
KITE-363 | KITE-363 | Phase 1 Clinical | Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
Rituximab biosimilar(Shandong New Time Pharmaceutical) | H-02; F-007 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details |
Odronextamab | REGN-1979 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) | CM-355 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
Epcoritamab | GEN-3013 | Phase 3 Clinical | Genmab, Abbvie Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Glofitamab | RO-7082859; RG-6026 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma | Details |
Mosunetuzumab | RG-7828; BTCT-4465A; RO-7030816 | Phase 3 Clinical | Genentech Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Phase 1 Clinical | Fujian Medical University | Lymphoma, Large B-Cell, Diffuse | Details | |
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) | B001 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin | Details |
JMT-601 | JMT-601 | Phase 1 Clinical | Shanghai Jinmante Biological Technology Co Ltd | Lymphoma, Non-Hodgkin | Details |
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Lymphoma, Large B-Cell, Diffuse | Details | |
Rituximab biosimilar (Hualan Biological Engineering) | WBP-263 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin | Details |
MRG001 | MRG-001 | Phase 2 Clinical | Shanghai Miracogen Inc | Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult; Lymphoma, Non-Hodgkin | Details |
Recombinant humanized monoclonal antibody MIL62 | Phase 3 Clinical | Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
This web search service is supported by Google Inc.